Try our Advanced Search for more refined results
(DPP)FWK Holdings, LLC v. Merck & Co., Inc. et al
Case Number:
2:18-cv-00023
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- DLA Piper
- Gibson Dunn
- Glasser & Glasser
- Goldman Ismail
- Hagens Berman
- Hilliard & Shadowen
- Kaufman & Canoles
- Kessler Topaz
- Lieff Cabraser
- Morgan Lewis
- Sperling & Slater
- Vanek Vickers
Companies
- Cardinal Health Inc.
- Glenmark Pharmaceuticals Ltd.
- H.D. Smith LLC
- McKesson Corp.
- Merck & Co. Inc.
- Supervalu Inc.
- Wegmans Food Markets Inc.
Sectors & Industries:
-
October 18, 2018
Glenmark Moves To Ax Zetia Pay-For-Delay Claims
Glenmark Pharmaceuticals Inc. has asked a Virginia federal judge to nix a suit accusing it of conspiring with Merck & Co. to delay production of a competitor to Merck's cholesterol treatment Zetia, saying that a private settlement with Merck did not prevent the launch of lower-priced alternatives.
-
April 02, 2018
Merck Says Holding Co. Must Arbitrate Pay-For-Delay Claims
Merck & Co. urged a Virginia federal judge on Monday to ax allegations it conspired with generics manufacturer Glenmark Pharmaceuticals Inc. to delay production of a competitor to cholesterol treatment Zetia, saying the suit is subject to an arbitration clause in the company's distribution agreement.
-
January 17, 2018
Merck, Glenmark Stifled Cholesterol Drug Market, Suit Says
Merck & Co. and generics manufacturer Glenmark Pharmaceuticals Inc. were hit with a putative class action in Virginia federal court Wednesday claiming an agreement to keep a generic version of cholesterol treatment Zetia off the market for five years created an unlawful monopoly.